Piper plays down significance of Tesla Autopilot case in Florida
On Monday, Oppenheimer analysts adjusted their outlook on Aquestive Therapeutics stock (NASDAQ:AQST), reducing the price target to $7.00 from $15.00 while maintaining an Outperform rating. Currently trading at $2.71, the stock has shown significant volatility, gaining over 15% in the past week. According to InvestingPro data, analyst targets range from $4.75 to $15.00, with a strong buy consensus. The revision follows the company’s recent financial disclosures for the first quarter of 2025 and updates on its corporate activities.
Aquestive Therapeutics recently submitted a New Drug Application (NDA) for Anaphylm to the FDA on April 1, 2025. The company anticipates receiving feedback from the FDA next month, with a potential action date set for late January or early February of 2026. Preparations for a potential advisory committee meeting are currently underway.
The analysts noted the company’s continued efforts in commercialization, including expanding its commercial team and increasing awareness about anaphylaxis. Aquestive is also engaging with payers and planning to collaborate with regulators outside the United States to bolster its financial standing. InvestingPro analysis shows the company maintains a FAIR financial health score, with more cash than debt on its balance sheet and strong liquidity ratios. Discover more insights with InvestingPro’s comprehensive research report, covering what really matters for informed investment decisions.
In light of its focus on the Anaphylm launch, Aquestive is currently deprioritizing other projects. This includes the decision not to appeal the court ruling on Libervant and postponing the Phase 2 trial of AQST-108 to the first half of 2026.
Despite the lowered price target, Oppenheimer’s outlook on Anaphylm remains unchanged, reflecting their valuation approach. The analysts continue to assume coverage of Aquestive Therapeutics with an Outperform rating. Based on InvestingPro’s Fair Value analysis, the stock appears fairly valued at current levels, with additional ProTips available for subscribers.
In other recent news, Aquestive Therapeutics reported a challenging first quarter of 2025, with earnings per share at -$0.24, missing analysts’ expectations of -$0.16. Revenue also fell short, coming in at $8.7 million compared to the anticipated $12.23 million. The company has revised its 2025 revenue guidance to a range of $44-$50 million, reflecting ongoing challenges. Raymond (NSE:RYMD) James maintained an Outperform rating on Aquestive Therapeutics with a price target of $7.00, emphasizing the firm’s focus on advancing the Anaphylm product. Aquestive completed its New Drug Application filing for Anaphylm, with FDA acceptance expected in June and a potential launch in early 2026. The company is preparing for potential advisory committee meetings due to the new delivery method for Anaphylm. Following a court ruling against Libervant, Aquestive has suspended promotion of the product until 2027, resulting in a lower revenue forecast but also cost savings. Despite these setbacks, Aquestive remains financially prepared, with approximately $69 million in cash as of the first quarter, expected to fund operations into 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.